secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003882
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences raises $108.9M in private placement; preliminary cash $123.9M
-------------------------------------------------------------------------------

- Gross proceeds ~$108.9M from 16,973,103 shares at $5.53/share and 2,712,478 pre-funded warrants at $5.529 each.
- Net proceeds ~$104.1M after fees; closing expected January 11, 2024.
- Preliminary unaudited cash, equivalents and securities of $123.9M as of Dec 31, 2023 (excluding PIPE proceeds).
- Clinical milestones: SGT-003 safety update mid-2024, initial data Q3 2024; SGT-501 IND submission Q1 2025.
- Investors include Perceptive Advisors, Adage Capital, Deerfield, Invus, Janus Henderson, Vestal Point, Bain Capital, RA Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312524003882/0001193125-24-003882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312524003882/d690167d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer